Literature DB >> 8369028

Searching for inaccuracy in clinical laboratory testing using Medicare data. Evidence for prothrombin time.

S T Mennemeyer1, J W Winkelman.   

Abstract

OBJECTIVE: To determine if the occurrence of health outcomes following clinical laboratory testing can be used to identify types of laboratories that may be having higher than expected error rates.
DESIGN: Retrospective analysis of Medicare Part B outpatient claims, Part A hospitalization bills, and death records using a case-control study.
SETTING: Medicare records from six carrier territories were sampled during the period 1985 through 1987. PATIENTS: A total of 14,755 Medicare patients receiving a prothrombin time test in either a physician office laboratory or a commercial laboratory. OUTCOME MEASURES: Occurrence of a hospitalization for stroke or acute myocardial infarction, death, or no adverse outcome within 6 days of a prothrombin time.
RESULTS: In physician office laboratories where prothrombin time test volume is below 40 per month, the odds that a tested patient will experience a stroke or an acute myocardial infarction are up to 1.96 and 3.43 times greater, respectively, than for a similar patient tested in a commercial laboratory. Switching from one laboratory to another between successive prothrombin time tests increased the odds of a stroke or an acute myocardial infarction by 1.57 and 1.32, respectively. Patients in two states with strong laboratory regulatory programs had fewer adverse outcomes.
CONCLUSION: Examining patient outcomes subsequent to clinical laboratory testing may be a useful tool for clinical laboratory quality assurance.

Entities:  

Mesh:

Year:  1993        PMID: 8369028

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Evidence based practice: clinicians' use and attitudes to near patient testing in hospitals.

Authors:  T A Gray; D B Freedman; D Burnett; A Szczepura; C P Price
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

2.  Where should oral anticoagulation monitoring take place?

Authors:  F D Hobbs; D A Fitzmaurice
Journal:  Br J Gen Pract       Date:  1997-08       Impact factor: 5.386

3.  Using healthcare claims data for outcomes research and pharmacoeconomic analyses.

Authors:  H G Birnbaum; P Y Cremieux; P E Greenberg; J LeLorier; J A Ostrander; L Venditti
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.